3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Rituximab
17
Cyclophosphamide
8
zanubrutinib
7
Bendamustine Hydrochloride
7
obinutuzumab
6
Lenalidomide
6
venetoclax
5
blinatumomab
5
acalabrutinib
5
Vincristine
5
fludarabine
4
Prednisone
4
Methotrexate
4
Doxorubicin
4
Cytarabine
4
Brentuximab Vedotin
4
ibrutinib
3
Specimen Handling
3
Dexamethasone
3
Crizotinib
3
tisagenlecleucel
2
tafasitamab
2
polatuzumab vedotin
2
pirtobrutinib
2
pegaspargase
2
idelalisib
2
duvelisib
2
axicabtagene ciloleucel
2
avapritinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
ublituximab
×
Lymphoid
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA